MIRAPEX®
Overview
MIRAPEX® Prolonged-Release Tablets (0.375 mg & 0.75 mg & 1.5 mg)
MIRAPEX® is indicated as a treatment of the signs and symptoms of Parkinson's disease (PD).1 There are Mirapex tablets for immediate-release (IR) and prolonged- release (PR) respectively1,2.
Product overview
Mirapex® PR Tablets is indicated in the treatment of the signs and symptoms of PD. 1 Mirapex® IR Tablets is indicated in the treatment of signs and symptoms of idiopathic PD and idiopathic Restless Legs Syndrome.2
Product key facts
Indication
Mirapex® is indicated as a treatment of the signs and symptoms of PD including patients with early PD, advanced PD, and restless legs syndrome.1
Active ingredients
Pramipexole
Legal category
Prescription only medicine
Administration form
Either IR or PR tablets should be taken orally, swallowed with water, and can be taken either with or without food.1,2 PR tablets must be swallow whole and must not be chewed, crushed, or divided.1
Dosage form
IR: 0.25 mg and 1.0 mg tablet
PR: 0.375 mg, 0.75 mg, and 1.5 mg tablet
Packsizes
MIRAPEX® IR:
Tablets of 0.25 and 1.0 mg: 2 -1000’s aluminums blister in paper box.2
MIRAPEX® PR:
0.375mg white to off-white, round, biconvex, bevel-edged, extended-release tablets debossed with ”P1” on one side and the Boehringer Ingelheim company symbol on the other side.1
0.75mg white to off-white, round, biconvex, bevel-edged, extended-release tablets debossed with ”P2” on one side and the Boehringer Ingelheim company symbol on the other side.1
1.5mg white to off-white, oval, biconvex, extended-release tablets debossed with ”P3” on one side and the Boehringer Ingelheim company symbol on the other side.1
Storage
Store under 30°C. Protect from exposure to high humidity. Store in a safe place out of the reach of children.1,2
Footnotes:
-
IR, immediate-release; PD, Parkinson's disease; PR, prolonged- release.
References:
-
MIRAPEX® Prolonged-Release Tablets 0.375 mg & 0.75 mg & 1.5 mg. approved package insert. Approved in 08 Oct 2019.
-
Mirapex® Tablets 0.25 mg & 1.0 mg. approved package insert. Approved in 08 Oct 2019.
